


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	10/598,777
		<b>Filing Date</b>	September 11, 2006
		<b>First Named Inventor</b>	Anja FECHER, <i>et al.</i>
		<b>Art Unit</b>	1625
		<b>Examiner Name</b>	Rita J. DESAI
<b>Sheet</b>	1 of 4	<b>Attorney Docket Number</b>	66535.000013



U.S. PATENT DOCUMENTS					
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2004/0162323	08-19-2004	Allergan	
	2.	US 4,808,608	02-29-1989	Krauss	

FOREIGN PATENT DOCUMENTS								
*Examiner Initial	Cite No	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
	3.	EP	1170594	01-09-2002	Pfizer		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	4.	EP	1413306	04-28-2004	Warner-Lambert Co.		<input type="checkbox"/>	<input type="checkbox"/>
	5.	EP	1435356	07-07-2004	Warner-Lambert Co.		<input type="checkbox"/>	<input type="checkbox"/>
	6.	WO	1997/00853	01-09-1997	Shionogi & Co.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	7.	WO	1998/25915	06-18-1998	Shionogi & Co.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	8.	WO	1998/25919	06-18-1998	Shionogi & Co.		<input type="checkbox"/>	<input type="checkbox"/>
	9.	WO	1999/62555	12-09-1999	Shionogi & Co.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	10.	WO	2001/14882	03-01-2001	BML, Inc.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	11.	WO	2001/78697	10-25-2001	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	12.	WO	2001/79169	10-25-2001	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	13.	WO	2001/94309	12-13-2001	Shionogi & Co.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	14.	WO	2002/072820	09-19-2002	Genoway		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>

<b>EXAMINER SIGNATURE</b>	/Rita Desai/	<b>DATE CONSIDERED</b>	12/03/2009
---------------------------	--------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.D./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	10/598,777
		<b>Filing Date</b>	September 11, 2006
		<b>First Named Inventor</b>	Anja FECHER, <i>et al.</i>
		<b>Art Unit</b>	1625
		<b>Examiner Name</b>	Rita J. DESAI
<b>Sheet</b>	2 of 4	<b>Attorney Docket Number</b>	66535.000013

FOREIGN PATENT DOCUMENTS								
*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code	Number-Kind Code (if known)				YES	NO
	15.	WO	2002/094830	11-28-2002	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	16.	WO	2002/32892	04-25-2002	Merck & Co.		<input type="checkbox"/>	<input type="checkbox"/>
	17.	WO	2002/36583	05-10-2002	Shionogi & Co.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	18.	WO	2003/008964	01-30-2003	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	19.	WO	2003/008978	01-30-2003	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	20.	WO	2003/062200	07-31-2003	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	21.	WO	2003/066046	08-14-2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	22.	WO	2003/066047	08-14-2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	23.	WO	2003/097042	11-27-2003	Shionogi & Co.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	24.	WO	2003/101961	12-11-2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	25.	WO	2003/101981	12-11-2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	26.	WO	2004/007451	01-22-2004	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	27.	WO	2004/032848	04-22-2004	Millennium Pharma.		<input type="checkbox"/>	<input type="checkbox"/>
	28.	WO	2004/035543	04-29-2004	Warner-Lambert Co.		<input type="checkbox"/>	<input type="checkbox"/>
	29.	WO	2004/039807	05-13-2004	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	30.	WO	2004/058164	07-15-2004	Tularik		<input type="checkbox"/>	<input type="checkbox"/>
	31.	WO	2004/074240	09-02-2004	Taisho Pharma.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	32.	WO	2004/078719	09-16-2004	Ono Pharma.		<input checked="" type="checkbox"/> Abstract	<input type="checkbox"/>
	33.	WO	2004/089884	10-21-2004	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>

<b>EXAMINER SIGNATURE</b> /Rita Desai/	<b>DATE CONSIDERED</b> 12/03/2009
----------------------------------------	-----------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.D./~~

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	<b>10/598,777</b>
		<b>Filing Date</b>	<b>September 11, 2006</b>
		<b>First Named Inventor</b>	<b>Anja FECHER, <i>et al.</i></b>
		<b>Art Unit</b>	<b>1625</b>
		<b>Examiner Name</b>	<b>Rita J. DESAI</b>
<b>Sheet</b>	<b>3 of 4</b>	<b>Attorney Docket Number</b>	<b>66535.000013</b>

FOREIGN PATENT DOCUMENTS								
*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code	Number-Kind Code (if known)				YES	NO
	34.	WO	2004/089885	10-21-2004	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	35.	WO	2004/096777	11-11-2004	Bayer Healthcare AG		<input type="checkbox"/>	<input type="checkbox"/>
	36.	WO	2004/106302	12-09-2004	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	37.	WO	2004/111047	12-23-2004	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	38.	WO	2004/103970	12-02-2004	Merck Frosst Canada		<input type="checkbox"/>	<input type="checkbox"/>
	39.	WO	2005/007094	01-27-2005	Tularik, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
	40.	WO	2005/018529	03-03-2005	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	41.	WO	2005/094816	10-13-2005	Actelion Pharma.		<input type="checkbox"/>	<input type="checkbox"/>
	42.	WO	2005/019171	03-03-2005	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	43.	WO	2006/021418	03-02-2006	Actelion Pharma.		<input type="checkbox"/>	<input type="checkbox"/>
	44.	WO	2006/070325	07-06-2006	Actelion Pharma.		<input type="checkbox"/>	<input type="checkbox"/>
	45.	WO	2008/017989	02-14-2008	Actelion Pharma.		<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS				
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	46.	ISHIZUKA, T., "Ramatroban (BAY u 3405): A Novel Dual Antagonist of TXA2 RECEPTOR AND crtH2, A Newly Identified Prostaglandin D2 Receptor", Cardiovascular Drug Reviews, Vol. 22, No. 2, pages 71-90 (2004)	<input type="checkbox"/>	<input type="checkbox"/>
	47.	ROBARGE, M., "Isosteric Ramatroban Analogs: Selective and Potent CRTH-2 Antagonists", Bioorganic & Medicinal Chemistry Letters 15, pages 1749-1753 (2005)	<input type="checkbox"/>	<input type="checkbox"/>

<b>EXAMINER SIGNATURE</b> /Rita Desai/	<b>DATE CONSIDERED</b> 12/03/2009
----------------------------------------	-----------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.D./~~

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	10/598,777
		<b>Filing Date</b>	September 11, 2006
		<b>First Named Inventor</b>	Anja FECHER, <i>et al.</i>
		<b>Art Unit</b>	1625
		<b>Examiner Name</b>	Rita J. DESAI
<b>Sheet</b>	4 of 4	<b>Attorney Docket Number</b>	66535.000013

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS			
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION
			YES      NO
	48.	ULVEN, T., "Minor Structural Modifications Convert the Dual TP/CRTH2 Antagonist Ramatroban into a Highly Selective and Potent CRTH2 Antagonist", Journal of Medicinal Chemistry, 48(4) pages 897-900, (2005)	<input type="checkbox"/> <input type="checkbox"/>

<b>EXAMINER SIGNATURE</b> /Rita Desai/	<b>DATE CONSIDERED</b> 12/03/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.D./